GSC
VRTX icon

G&S Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

G&S Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,267
Closed -$510K – 134
2024
Q4 		$510K Buy
1,267
+614
+94% +$285K 0.21% 98
2024
Q3 		$304K Hold
653
– – 0.13% 112
2024
Q2 		$321K Sell
653
-36
-5% -$15.6K 0.14% 106
2024
Q1 		$288K Sell
689
-8
-1% -$3.38K 0.13% 113
2023
Q4 		$284K Sell
697
-149
-18% -$55K 0.13% 103
2023
Q3 		$294K Hold
846
– – 0.15% 106
2023
Q2 		$298K Sell
846
-492
-37% -$166K 0.14% 108
2023
Q1 		$422K Sell
1,338
-69
-5% -$20.7K 0.19% 91
2022
Q4 		$406K Buy
+1,407
New +$429K 0.18% 90
2020
Q3 		– Sell
-1,063
Closed -$309K – 93
2020
Q2 		$309K Buy
+1,063
New +$288K 0.28% 56

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

G&S Capital's VRTX Position: Q1 2025 in Review

G&S Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 1,267 shares — an estimated $510K sold.

G&S Capital first reported a position in VRTX in Q2 2020 and held it in 10 quarters. The position peaked at $510K in Q4 2024. 1,616 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • G&S Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • G&S Capital sold 1,267 Vertex Pharmaceuticals shares in Q1 2025, an estimated $510K.
  • G&S Capital first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 10 quarters.
  • G&S Capital's Vertex Pharmaceuticals position peaked at $510K in Q4 2024.
  • 1,616 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on G&S Capital's 13F filing for Q1 2025, filed 25 Apr 2025.